

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

PAR PHARMACEUTICAL, INC., and ENDO
PAR INNOVATION COMPANY, LLC

C.A. No. 23-866-JLH-LDH

Plaintiffs,

v.

ZYDUS PHARMACEUTICALS (USA) INC.
and ZYDUS LIFESCIENCES LTD.

Defendants.

APPENDIX OF EXHIBITS FOR JOINT CLAIM CONSTRUCTION BRIEF

Dated: May 31, 2024

Brian E. Farnan (Bar No. 4089)
Michael J. Farnan (Bar No. 5165)
FARNAN LLP
919 North Market St., 12th Floor
Wilmington, DE 19801
Tel: (302) 777-0300
Fax: (302) 777-0301
bfarnan@farnanlaw.com
mfarnan@farnanlaw.com

Martin J. Black (admitted *pro hac vice*)
Sharon K. Gagliardi (admitted *pro hac vice*)
Brian M. Goldberg (admitted *pro hac vice*)
Luke M. Reilly (admitted *pro hac vice*)
Daniel R. Roberts (admitted *pro hac vice*)
DECHERT LLP
Cira Centre
2929 Arch Street
Philadelphia, PA 19104
Tel: (215) 994-4000
martin.black@dechert.com
sharon.gagliardi@dechert.com
brian.goldberg@dechert.com

Pilar G. Kraman (#5199)
Alexis N. Stombaugh (#6702)
Jennifer Siew (#7114)
YOUNG CONAWAY STARGATT
& TAYLOR, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
(302) 571-6600
pkraman@ycst.com
astombaugh@ycst.com
jsiew@ycst.com

Of counsel:

Michael J. Gaertner
James T. Peterka
Terry Canade
Carolyn A. Blessing
Jacob C. Britz
LOCKE LORD LLP
111 South Wacker Drive
Chicago, IL 60606

luke.reilly@dechert.com
daniel.roberts@dechert.com

Jonathan D.J. Loeb, Ph.D. (admitted *pro hac*
vice)
DECHERT LLP
2400 W. El Camino Real, Suite 700
Mountain View, CA 94040-1499
Tel: (650) 813-4995
jonathan.loeb@dechert.com

*Attorneys for Plaintiffs Par Pharmaceutical,
Inc. and Endo Par Innovation Company, LLC*

(312) 443-0700

Zhibin Li
LOCKE LORD LLP
Brookfield Place, 200 Vesey Street
New York, New York 10281
(212) 415-8600

*Attorneys for Defendants Zydus
Pharmaceuticals (USA) Inc., and Zydus
Lifesciences Limited*

INDEX OF EXHIBITS

EXHIBIT	DESCRIPTION	JOINT APPENDIX
Exhibit 1	U.S. Patent No. 11,779,587	JA1 – JA60
Exhibit 2	U.S. Patent No. 11,717,524	JA61 – JA118
Exhibit 3	Excerpts from Zydus Pharms. (USA) Inc. and Zydus Lifesciences Ltd.’s Initial Invalidity Contentions	JA119 – JA126
Exhibit 4	U.S. Patent No. 11,602,537	JA127 – JA184
Exhibit 5	March 29, 2024 Declaration of Dr. David R. Dodds and accompanying Exhibits A-F	JA185 – JA343
Exhibit 6	Declaration of Dr. Steven W. Baertschi and accompanying Exhibits 1-6	JA344 – JA514
Exhibit 7	Excerpts from the file history of U.S. Patent No. 11,779,587, July 11, 2023, Amendment and Response to Non-Final Office Action	JA515 – JA531
Exhibit 8	May 14, 2024 Rebuttal Declaration of Dr. David R. Dodds and accompanying Exhibits F-G	JA532 – JA609
Exhibit 9	May 28, 2024 Responsive Declaration of Dr. Steven W. Baertschi	JA610 – JA620
Exhibit 10	ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2) (“ICH Q3A”)	JA621 – JA636
Exhibit 11	Excerpts from the file history of U.S. Patent No. 11,779,587, Apr. 17, 2023, Non-Final Rejection	JA637 – JA653
Exhibit 12	Excerpts from the file history of U.S. Patent No. 11,717,524	JA654 – JA726